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Abstract
In a phase III trial of patients with unresectable stage III nonesmall-cell lung cancer and a poor prognosis,
palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy
alone, except among performance status 2 patients. The results of the present exploratory subgroup analysis
indicate that elderly patients with poor prognosis can also experience health-related quality of life and survival
benefits from CRT, provided the treatment modalities have been adapted to a palliative setting.
Background: In a phase III trial of patients with unresectable, locally advanced, stage III nonesmall-cell lung
cancer (NSCLC) with a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly
better outcome than chemotherapy alone, except among performance status (PS) 2 patients. In the present
subgroup analysis, we evaluated the effect on patients aged  70 years (42% of all included) compared with
patients aged < 70 years enrolled in the trial. Patients and Methods: All patients received 4 courses of intravenous
carboplatin and oral vinorelbine. The experimental arm also received radiotherapy (42 Gy in 15 fractions). The
included patients were required to have large tumors (> 8 cm), weight loss (> 10% within the previous 6 months)
and/or PS 2. Results: The overall survival was increased among the CRT patients in both age groups, but the
difference was significant only in patients aged < 70 years (median survival, 14.8 vs. 9.7 months; P ¼ .001; age
 70 years, median survival, 10.2 vs. 9.1 months; P ¼ .09). Patients aged  70 years experienced better preserved
health-related quality of life (QOL) and significantly less hematologic toxicity. The 2- and 3-year survival was
significantly increased in both age groups receiving CRT. Conclusion: Elderly patients aged  70 years with
unresectable, stage III, locally advanced, NSLCL and a poor prognosis can tolerate CRT with the doses adjusted
to age and palliative intent. These results indicate that CRT can provide both survival and QOL benefits in elderly
patients, except for those with PS 2 or worse. The male predominance in the  70-year-age group and the reduced
chemotherapy intensity for the patients aged > 75 years might explain the lack of significant survival improvement
among those patients aged  70 years.
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Among the approximately 2900 Norwegians annually diagnosed
with lung cancer, the median age at diagnosis is 70 years, regardless
of stage.1-3 Advanced age has often been associated with a poor
performance status (PS) and comorbidities. Elderly patients with
lung cancer have been significantly underrepresented in clinical
trials,4 and advanced age has been a prevalent reason for not
administering treatment according to the guidelines.5,6 Despite
the clear survival benefits, most elderly patients with advanced
nonesmall-cell lung cancer (NSCLC) have been undertreated or do
not receive chemotherapy.7,8
Several explanations can be found. First, elderly patients with
locally advanced (LA)-NSCLC will experience more toxicity and
side effects from combination chemotherapy and chemo-
radiotherapy than will younger patients.9 Second, physicians might
be reluctant to offer treatment known to give troublesome side
effects owing to the unwarranted assumption that elderly patients
will not benefit from cytotoxic therapy.10,11 Trials that have
included elderly patients, and even more so, elderly patients with a
poor prognosis and unresectable, stage III LA-NSCLC, have been
lacking. The treatment recommendations for this group have often
conflicted. Some investigators have questioned the indications
for concomitant chemoradiotherapy (CRT),12,13 and others have
recommend CRT only for patients with a good performance
status (PS).14 Some have simply considered patient age  75 years
a contraindication for CRT.15 An additional problem has been
that few of the existing trials concerning this patient group have
adhered to the standard treatment of unresectable stage III
LA-NSCLC.11,13 It has been tenaciously argued that clinical trials
of treatment in older populations are necessary.8,16
It should be possible to adjust the therapies and doses to the
patient’s age and physical condition and, thus, still offer older pa-
tients a meaningful treatment regimen. Palliative radiation doses
might alleviate symptoms, with resultant local control, and the
generalized cytotoxicity from adjusted chemotherapy doses might
delay the development of metastases. In a recently published study,
Temel et al17 concluded that patients receiving early palliative care
for NSCLC were in need of less aggressive care at the end of life and
had longer survival. Therefore, additional research on palliative
treatment using CRT has been recommended, especially including
symptoms and validated health-related quality of life (HRQoL) data
as outcomes.18
We conducted a national phase III trial, comparing palliative
concurrent CRT and palliative chemotherapy alone in patients with
nonresectable LA-NSCLC and a poor prognosis.19 Age was not an
exclusion criterion, and 42% of the randomized patients were
aged  70 years and 22% were aged  75 years. Because limited
treatment outcome data have been available for elderly patients
with lung cancer, we present the data from a subset analysis that
focused on the efficacy, toxicity, and HRQoL in elderly patients
included in the phase III trial.
Patients and Methods
The Conrad study was an open, multicenter, phase III trial
comparing the efficacy and safety of palliative chemotherapy versus
palliative CRT in patients with stage III NSCLC and a poor
prognosis.19 The chemotherapy regimen consisted of 4 courses ofClinical Lung Cancer May 2015oral vinorelbine 60 mg/m2 on day 1 and 8 and intravenous
carboplatin (area under the curve, 5; Calvert’s formula) on day 1,
administered every 3 weeks. Patients aged > 75 years received
75% of the full dose. The patients in the experimental arm received,
in addition, thoracic radiotherapy with 42 Gy in 15 fractions
between the second and third chemotherapy course. This regimen
has been the standard palliative approach in Norway since the
1980s.20 The treatment and dosimetry planning were conducted
according to the participating institutions’ protocols.
Patients with nonresectable stage III LA-NSCLC and negative
prognostic factors were eligible, if they were not candidates for
radical radiotherapy (> 60 Gy) and had not received previous
chemotherapy. The cancer was staged according to the American
Joint Committee on Cancer, 7th edition.21 PS 2, weight loss
(> 10% within the previous 6 months), and a large tumor mass
( 8 cm) were considered negative prognostic factors. Only thoracic
and upper abdominal computed tomography (CT) imaging was
mandatory, and verified malignant pleural effusion was an exclusion
criterion. Positron emission tomography (PET)-CT was not widely
available in Norway during the enrollment period.
The Regional Ethics Committee of North Norway approved the
Conrad study, and all patients provided written informed consent
before study participation. The details of the original study have
been previously published.19
Response Assessment
The primary endpoint of the Conrad study was overall survival.
The secondary endpoints were the interval to progression, HRQoL,
and treatment toxicity. Questionnaires developed by the European
Organization for Research and Treatment of Cancer (EORTC)
regarding HRQoL were distributed to the patients at randomiza-
tion, at every chemotherapy course, and every 8 weeks after treat-
ment completion.22 Before each chemotherapy course, blood
samples and information about esophagitis were obtained. A sum-
mary of the chemotherapy and radiation administered was provided
for each patient by all the participating centers. The PS and disease
status were recorded at all follow-up visits (weeks 12, 20, 28, 36, 44,
and 52). Adverse events were graded according to the Common
Terminology Criteria for Adverse Events, version 3.0.
Definition of the Elderly Subgroup and Study Aims
In accordance with common practice, we defined the elderly as
patients aged  70 years.4,13,23-25 Age was a stratification factor
specified in the original protocol. The aims of the present analysis
were to (1) explore the efficacy and safety of palliative CRT in
elderly patients (aged  70 years) with nonresectable LA-NSCLC
and a poor prognosis enrolled in a phase III study setting and
(2) compare the results with those of younger patients. Age was
treated as a binary variable in all analyses.
Statistical Analysis
Overall survival and the interval to progression were compared
using the Kaplan-Meier method and the log-rank test, using the
intention to treat. The date of death was chosen as the date of
progression if no other information on progression was available.
On multivariate analysis, the estimation and 95% confidence in-
terval (CI) of the hazard ratio (HR) were calculated using a Cox
Hans H. Strøm et alproportional hazard model that included age, gender, weight loss,
tumor size, PS, and cancer stage. Not to lose information, age and
tumor size were not dichotomized in the present analysis.
The chi-square test and the Fisher exact test, in the Statistical
Package for Social Sciences, were used to compare the patient
characteristics and evaluate the treatment-related differences be-
tween the patient groups. P values < .05 were considered statisti-
cally significant. The PS was compared using analysis of variance
(ANOVA) and the nonparametric Mann-Whitney U test.
The responses to the EORTC questionnaires were analyzed ac-
cording to the EORTC scoring manuals.26 The changes in the
mean score relative to time were calculated by subtracting the
baseline score, and a difference of  10 points was considered
clinically relevant. Repeated ANOVA measures were used to analyze
the HRQoL changes over time. The nonparametric Mann-Whitney
U test was used to compare the scores. A higher score for the
symptom domains indicated more pronounced symptoms, but a
higher score for the functional domains indicated better function.
Results
Patients and Study Treatment
From November 2006 to November 2011, 191 patients were
included from 25 hospitals in Norway. The characteristics of theTable 1 Patient Characteristics Stratified by Age and Treatment
Characteristic
Age < 70 Years (n [ 109)





Male 34 (63) 30 (55)
Female 20 (37) 25 (46)
Performance status N
0-1 44 (82) 44 (80)
2 10 (18) 11 (20)
Tumor size (cm) N
<8 30 (56) 22 (40)
8 24 (44) 33 (60)
Weight loss (%) N
<10 36 (67) 34 (62)
10 18 (33) 21 (38)
Stage N
IIIA 24 (44) 18 (33)
IIIB 30 (56) 37 (67)
Histologic type N
Squamous cell carcinoma 17 (31) 26 (47)
Adenocarcinoma 22 (41) 17 (31)
Large cell carcinoma 3 (5.6) 1 (1.8)
Other 12 (22) 11 (20)
Data presented n (%).
Abbreviations: CRT ¼ chemoradiotherapy; NS ¼ nonsignificant.
aFisher’s 2-sided P value for testing the null hypothesis of no difference between patients receiving
bFisher’s 2-sided P value for testing the null hypothesis of no difference between the 2 age groups188 eligible patients are presented in Table 1. Of the 191 pa-
tients, 3 were excluded; 1 had stage IV disease, 1 had synchronous
lung and uterine cancer, and 1 had a neuroendocrine tumor.
Significantly more men than women were included among the
patients aged  70 years receiving CRT compared with the cor-
responding group who was < 70 years old. Stage IIIB was pre-
dominant in the youngest patient group, regardless of treatment,
and stage IIIA was predominant among the oldest. The difference
with respect to stage was statistically significant for patients
receiving CRT. Apart from these findings, no statistically signif-
icant differences were found in the clinical features between the
two age groups.
Survival
The overall survival increased for both age groups among patients
receiving CRT, but the improvement was statistically significant
only for the patients aged < 70 years (Figure 1A,B). The 2- and
3-year survival was significantly increased in both age groups
receiving CRT (Figure 1C). Among the elderly with PS 2, no dif-
ference was seen in survival between the two treatment arms (n ¼
19; chemotherapy, 7.9 months; CRT, 7.8 months; P ¼ .64). On
multivariate analysis of age, gender, weight loss, tumor size, PS,
and stage, PS was the only clinical factor with a significant effectAge ‡ 70 Years (n [ 79)




25 (63) 30 (77)
15 (37) 9 (23)
S NS NS
31 (78) 29 (75)
9 (22) 10 (24)
S NS NS
19 (47) 16 (41)
21 (53) 23 (59)
S NS NS
27 (68) 21 (54)
13 (32) 18 (46)
S NS .03
22 (55) 22 (56)
18 (45) 17 (44)
S NS NS
19 (47) 20 (51)
9 (23) 14 (36)
1 (2.5) 0
11 (27) 5 (13)
chemotherapy or CRT.
receiving CRT.
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Figure 1 Overall Survival for (A) Patients Aged < 70 Years and (B) Patients Aged ‡ 70 Years. (C) Survival at 1, 2 and 3 Years According
to Age and Treatment. (D) Performance Status According to Age Group, Registered Through the First Year
Abbreviations: Chemo ¼ chemotherapy; CI ¼ confidence interval; CRT ¼ chemoradiotherapy.
Elderly Poor Prognosis Patients and Palliative Concurrent CRT
186 - Clinical Lung Cancer May 2015
Hans H. Strøm et alon survival (HR, 1.86 for PS 0-1 vs. PS 2; 95% CI, 1.26-2.72;
P ¼ .002).
Treatment Discontinuation and Toxicities
The mean number of completed chemotherapy cycles ranged
from 3.5 to 3.6 in all 4 groups (Table 2). Chemotherapy discon-
tinuation because of disease progression was more prevalent among
the younger patients receiving chemotherapy only. A similar
discontinuation rate was not observed among patients aged  70
years. In the CRT group aged < 70 years, the mean number of
radiation fractions received was 14.6. For patients aged  70 years,
it was 12.3.
No overall differences were seen in hematologic toxicities
between the two treatment modalities (Table 3), except for a
greater incidence of thrombocytopenia among the younger pa-
tients receiving CRT. Comparing the two age groups receiving
CRT, we found significantly fewer hematologic toxicities and
fewer infections related to neutropenia among the elderly.
Esophagitis was less prominent among the elderly receiving CRTTable 2 Administered Therapy and Reasons for Discontinuation
Variable
Age < 70 Years
Chemotherapy
(n [ 54) CRT (n [ 55) 2P Valu
Chemotherapy
Cycles (n)
0 0 1 (1.8)
1 3 (5.6) 1 (1.8)
2 4 (7.4) 3 (5.5)
3 7 (13) 6 (11)
4 40 (74) 44 (80)
Discontinued
Disease progression 11 2 .008
Unacceptable toxicity 1 7 NS
Intercurrent disease 3 2 NS
Patient request 1 3 NS














Data presented as n (%).
Abbreviations: CRT ¼ chemoradiotherapy; NS ¼ nonsignificant.
aFisher’s 2-sided P value for testing the null hypothesis of no difference between patients receiving
bFisher’s 2-sided P value for testing the null hypothesis of no difference between the 2 age groupsthan among the younger patients, but the difference was not
significant.
HRQoL and PS
Of the 188 patients, 186 (99%) completed the HRQoL ques-
tionnaire at randomization. The median percentage of completed
questionnaires in the first 6 months after randomization ranged
from 84% to 86% in all groups, declining to a range of 67% to
75% during the final 6 months of the observation period.
To provide an adequate and clinically useful HRQoL assessment
of the two different treatment regimens, we chose to report three
functional (global QoL, physical function, and social function) and
four symptom (dysphagia, fatigue, pain, and dyspnea) domains
(Figure 2).27 The null hypothesis was that the variations in QoL
over time would be similar in the two age groups, depending on the
treatment. No significant difference was found in the mean score
between the age groups at baseline.
Among the patients receiving CRT, the variations in the
functional scores for patients aged  70 years were less pronouncedAge ‡ 70 Years
2P Valuebea
Chemotherapy
(n [ 40) CRT (n [ 39) 2P Valuea
0 0
1 (1.8) 1 (1.8)
4 (10) 8 (21)
4 (10) 1 (2.6)

















chemotherapy only or CRT.
receiving CRT.
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Table 3 Toxicity According to Age and Treatment
Toxicity
Age < 70 Years Age ‡ 70 Years
P ValuebChemotherapy CRT 2P Valuea Chemotherapy CRT 2P Valuea
Anemia (183 valid cases) NS NS
Grade 3 5 (9.8) 4 (7.4) 0 1 (2.6)
Grade 4 0 0 0 0
Neutropenia (183 valid cases) NS NS <.05
Grade 3 14 (28) 14 (26) 7 (18) 4 (11)
Grade 4 7 (14) 17 (32) 7 (18) 6 (16)
Thrombocytopenia (183 valid cases) <.05 NS <.05
Grade 3 3 (5.9) 6 (11) 0 0
Grade 4 1 (2.0) 3 (5.6) 0 0
Infections in relation to leukopenia
(170 valid cases)
NS NS <.05
1 11 (23) 16 (35) 5 (13) 7 (18)
2 1 (2.1) 4 (98) 0 0
3 0 0 1 (2.6) 0
Hospital admissions in relation to side effects
(170 valid cases)
NS <.01 NS
1 14 (30) 20 (43) 4 (10) 13 (35)
2 3 (6.4) 5 (11) 1 (2.6) 4 (11)
3 0 3 (6.4) 1 (2.6) 0
Esophagitis in relation to RT (157 valid cases) <.01 <.01 NS
Grade 1 3 (7.9) 8 (15) 1 (3.4) 8 (21)
Grade 2 1 (2.6) 19 (37) 3 (10) 16 (42)
Grade 3 1 (2.6) 20 (39) 0 7 (18)
Grade 4 0 0 (0) 0 0 (0)
Data presented as n (%).
Abbreviations: CRT ¼ chemoradiotherapy; NS ¼ nonsignificant; RT ¼ radiotherapy.
aFisher’s 2-sided P value for testing null hypothesis of no difference in parameter distribution between patients receiving chemotherapy or CRT.
bFisher’s 2-sided P value for testing null hypothesis of no difference in parameter distribution between the two age groups receiving CRT.
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less of age, the scores indicated that the functional domains
were best preserved among the patients receiving CRT. The
patients receiving only chemotherapy experienced a gradual
decline in all functions during the whole observation period,
which were most pronounced and clinically relevant among the
elderly.
Compared with the patients receiving chemotherapy alone,
dysphagia was significantly increased among the CRT patients
during the treatment period, regardless of age. However, this
symptom was most pronounced among the younger patients.
Regarding fatigue and dyspnea, the scores indicated no difference
between the groups, before the latter part of the observational
period. In the latter study period, the patients aged  70 years
receiving only chemotherapy reported more clinically relevant
symptoms than did the CRT patients.
The reported PS scores (Figure 1D) indicated a decreased PS for
patients treated with chemotherapy alone, regardless of age. Among
the patients administered CRT, only a transient decline was found
in the PS after treatment. This was normalized for both age groups
during the observational period.Clinical Lung Cancer May 2015Discussion
Our data have demonstrated that patients aged  70 years with
negative prognostic factors and nonresected, stage III LA-NSLCL
can tolerate CRT with the doses adjusted to age and a palliative
intent. After CRT, patients aged  70 years experienced signifi-
cantly increased two- and three-year survival, less pain, and better
preserved HRQoL than did patients in same age group who received
only chemotherapy. However, PS 2 patients did not experience a
survival benefit from palliative CRT compared with chemotherapy
alone, regardless of age.
For patients with a good PS and nonresectable LA-NSCLC,
CRT has been considered the standard therapy.14 For elderly pa-
tients, however, the best treatment approach has not been deter-
mined.12,28 In two recent Japanese studies of elderly patients with
unresectable LA-NSCLC receiving CRT, the reported median
survival was > 22 months. Both trials consisted almost entirely
of patients with PS 0 to 1, and the treatment was given with
curative intent (radiation 60 Gy).25,29 In a subanalysis of a phase III
trial, Jalal et al30 found a median survival period of 17.1 months
for patients aged  70 years who had received cisplatin and eto-
poside and concurrent chest radiation (59.4 Gy). They concluded
Figure 2 Health-Related Quality of Life (QOL) Scores Until One Year From Randomization. (A-C) Functional Scores (High Scores
Represent Good QOL). (D-G) Symptom Scores (High Scores Represent More Symptoms). Black Dotted Line Indicates
Chemotherapy Alone, Patient Age < 70 Years; Gray Dotted Line, Chemoradiotherapy (CRT) and Patient Age < 70 Years; Black
Solid Line, Chemotherapy Alone and Patient Age ‡ 70 Years; Gray Solid Line, CRT and Patient Age ‡ 70 Years
Hans H. Strøm et al
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190 -that fit older adults experienced greater rates of hospitalization
and toxicity. In a recent retrospective Brazilian study, Domingues
et al28 found an overall survival of 15.5 months among patients
aged  65 years with LA-NSCLC treated with CRT (radiation
dose  40 Gy).
These treatment regimens should be considered radical or
“curative.” Most patients with NSCLC have been diagnosed with
advanced disease and the elderly will have more comorbidities
than younger patients.9,31 Thus, only a few will be able to endure
radical treatment. However, the significant increase in two- and
three-year survival in our study indicates that CRT, with the doses
adjusted to a palliative intent, might be a practical and relevant
treatment alternative for elderly patients with negative prognostic
factors and comorbidities.
Several factors in our study reduced or prevented the treatment
effect in the experimental arm among the group aged  70 years. A
male predominance was present in our data (77% male in the older
vs. 55% in the younger CRT group). Women with lung cancer are
known to have a better prognosis than men, older women even
more than younger women.2,32 It can, in part, be explained by the
late diagnosis and more advanced disease in the men. Because we
recruited patients with poor prognostic factors from the original
phase III study, a male predominance could be expected.2,33
Another important factor was patient age. About 50% of our
older treatment group (age  70 years) was > 75 years old. In line
with the palliative intent and advanced age, these patients were
administered 25% reduced chemotherapy doses. These reductions
are expected to have influenced the survival rate negatively but
corresponded to the favorable hematologic profile among patients
aged  70 years, regardless of the treatment. The CRT patients
aged < 70 years experienced significantly more hematologic
toxicity. The relatively low overall survival in our data set might
imply that the chemotherapy dose for patients aged > 75 years was
reduced too liberally.
The hospital admissions related to side effects and esophagitis
were significantly increased among the elderly CRT patients. The
difference in hospital admissions related to side effects was most
prominent among the patients aged  70 years, possibly owing to
the dose-reduced chemotherapy in this age group. Nevertheless,
the rate of esophagitis and hematologic toxicity among the elderly
were in accordance with the findings from Kang et al.34 They re-
ported an incidence of treatment-related toxicity in the elderly that
was noticeably lower than previously reported.34 We should expect
that more modern planning techniques and radiologic equipment
will help to reduce the radiologic effects on the esophagus and bone
marrow in the future.
Today, most centers consider CT alone to be insufficient in the
diagnostic workup of patients with lung cancer. Magnetic resonance
imaging is considered more sensitive in detecting brain metastases
and PET-CT more sensitive in detecting other organ metastases.
Accordingly, using CT alone in the investigation might have
resulted in patients with more advanced disease being included in
our study. However, if this were so, this would only strengthen the
argument for the beneficial effects of CRT for subjects with a poor
prognosis.
Few previous studies have addressed HRQoL > 3 months after
radiotherapy in patients with LA-NSCLC. However, Wang et al35Clinical Lung Cancer May 2015and Pijls-Johannesma et al36 have described some general ten-
dencies that occur after CRT. Most functioning scores usually
decline over time. Symptoms such as hemoptysis, pain, and
cough tend to show improvement initially but usually increase
later during the disease course. Dysphagia is related to esopha-
gitis secondary to CRT and usually improves after radiotherapy
completion.
The social and physical function reported by patients aged
 70 years in our study followed this pattern to a certain extent.
The global QoL score illustrates the most prominent functional
benefit of CRT for the elderly, because these patients did not
experience any clinical relevant QoL reduction during treatment
or observation.
In accordance with earlier studies,36,37 the initial CRT-related
symptoms, such as dysphagia and pain in our study, were tran-
sient and less prominent among the elderly. From HRQoL in-
vestigations in two prospective CRT-based trials of patients with
stage III NSCLC, Hallqvist et al37 reported a gradual worsening
of dyspnea and fatigue during the observation period, regardless
of age. Among the patients aged  70 years in our study, the CRT
patients reported less dyspnea during the latter part of the
observation period compared with those administered chemo-
therapy only. The increase in the incidence of fatigue was clini-
cally relevant during treatment in the CRT groups; however, it
declined subsequently during the observation period to levels
slightly lower than those in the non-CRT patients. In contrast,
patients aged  70 years who received chemotherapy only had a
slight reduction in the incidence of fatigue during the treatment
period but experienced a clinically relevant increase during the
observation period.
In a HRQoL study of patients with NSCLC from 2001, Lan-
gendijk et al38,39 found that neither palliative nor radical radio-
therapy gave satisfactory palliation of respiratory symptoms in
patients followed up for 12 months. These data are in conflict with
our findings. Major problems were present in the cited HRQoL
study. The main problem was the poor HRQoL compliance rates,
because the response rates were as low as 28% to 68% for all scales,
except hemoptysis (83%). Because the response rate for several
of the function and symptom scores was < 38%, one might
question the validity of the HRQoL data from that study. In
addition, during the 17-year period since these patients were treated
(1994-1996), the ability to spare healthy tissue in the proximity of
tumors from radiation has developed with advances in modern
radiotherapy techniques.16
It could be argued that the apparent CRT-related beneficial
HRQoL effects we observed late in the observation period could be
explained by patient selection (ie, that after 10 months only those
with the best response remained). This objection would be appli-
cable to any study of malignancies with a short patient life expec-
tancy. The 1- and 2-year survival of 44% and 23%, respectively,
after CRT for patients aged  70 years, such as was seen in our
study, should be a strong argument for both the use of CRT and the
relevance of HRQoL recordings for 12 months after treatment
initiation.
Another objection to the relevance of HRQoL and PS regis-
tration late in the disease course is the declining compliance in
questionnaire completion as the disease progresses.40 However, the
Hans H. Strøm et aldecline in compliance was moderate and would be expected to
affect the study groups without introducing any biases.19
Conclusion
We have concluded that even in patients aged  70 years with
a poor prognosis, tailored CRT does not reduce HRQoL to any
clinical relevant degree. We found that PS and HRQoL can be
preserved, even late in the observation period after CRT.
Although CRT has routinely been reserved for younger fit pa-
tients, the results of the present exploratory analysis have indi-
cated that CRT can result in both survival and HRQoL benefits
to elderly patients with a poor prognosis and nonresectable LA
NSCLC, except for PS 2 patients, provided the treatment mo-
dalities have been adapted to a palliative setting. Given the low
frequency of hematologic toxicity, especially among patients aged
> 75 years, one might speculate that the chemotherapy dose was
reduced too low in our study.
Clinical Practice Points
 The treatment recommendations for elderly patients with
advanced NSCLC are often conflicting. Thus, many elderly
patients with advanced NSCLC will be undertreated or will not
receive chemotherapy. It has been tenaciously argued that clinical
trials of treatment in older populations are necessary.
 We found that, even in patients with a poor prognosis aged
 70 years, tailored CRT does not reduce HRQoL to any
clinical relevant degree. We also found that, except for PS 2 pa-
tients, the PS and HRQoL were preserved even late in the
observation period after CRT. Given the low frequency of
hematologic toxicity, especially among patients aged > 75 years,
one might speculate that the chemotherapy dose was reduced
too low in our study.
 CRT might give both survival and HRQoL benefits to elderly
patients with poor prognosis and nonresectable LA-NSCLC,
except for PS 2 patients, provided the treatment modalities are
adapted to a palliative setting.Acknowledgments
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